Spinocerebellar Ataxias Pipeline Insight

DelveInsight’s, “Spinocerebellar Ataxias – Pipeline Insights, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Spinocerebellar Ataxias pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Geography Covered

  • Global coverage

Spinocerebellar Ataxias Understanding

Spinocerebellar Ataxias: Overview

The Spinocerebellar ataxias (SCA) are a subset of hereditary cerebellar ataxias that are autosomal dominantly transmitted. They are progressive neurodegenerative diseases that share the clinical features of ataxia, which arise from the progressive degeneration of the cerebellum but can also affect other connected regions, including the brain stem. They are a highly heterogenous group of disorders with a complex genotype–phenotype spectrum; many SCAs are caused by CAG nucleotide repeat expansions that encode polyglutamine, and therefore, involve the toxic polyglutamine protein (polyQ).

The spinocerebellar ataxias (SCAs) are a large complex group of inherited neurodegenerative disorders characterized by progressive cerebellar ataxia, ocular motor abnormalities, and a range of other variable neurologic features, including retinopathy, optic atrophy, peripheral neuropathy, extrapyramidal symptoms, and cognitive dysfunction.


  • Gait ataxia and incoordination
  • Nystagmus/visual problems
  • Dysarthria
  • Extrapyramidal signs
  • Ophthalmoplegia
  • Cognitive impairment in specific SCAs


A phenotype-first approach remains pertinent in molecular diagnosis of rare genetic disorders. Clinicians should also consider genetic testing for primary episodic ataxias (EA). Advances in next-generation sequencing (NGS) have facilitated further insights into the molecular causes of SCA. Exome sequencing identifies less classical phenotype–genotype correlations and detects new mutations in known cerebellar genes.


Advancements in the understanding of pathophysiologic mechanisms facilitate the potential to find new therapeutic targets. Riluzole, a drug licensed for the treatment of ALS, was reconsidered for the treatment of patients with ataxia owing to its ability to inhibit presynaptic glutamate release and activate calcium-activated potassium channels.The anticonvulsant valproic acid has been proposed as a pharmacological treatment in SCA3/MJD for its neuroprotective properties as a pan-histone deacetylase inhibitor. Lithium carbonate was evaluated in 62 ambulatory patients with SCA3/MJD for 48 weeks, but no difference was seen in mean scores of the neurological scale for ataxia. Varenicline is a partial agonist of the α4β2 neuronal nicotinic acetylcholine receptor that is used to aid the cessation of smoking. Varenicline was anecdotally reported to have beneficial effects in patients with ataxia that were taking it as part of a smoking cessation programme. General supportive management options include physiotherapy, occupational therapy and speech therapy. Physiotherapy focused on improving gait, balance, coordination, posture and muscle strength is often recommended.

Spinocerebellar Ataxias Emerging Drugs Chapters

This segment of the Spinocerebellar Ataxias report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Spinocerebellar Ataxias Emerging Drugs

  • KPS-0373: Kissei Pharmaceutical

KPS-0373 is an l drug that is a TRH receptor agonist. It has recently completed Phase III trial of clinical study. It was originally developed by Kissei Pharmaceutical but now licensed to Shinogi.

Further product details are provided in the report……..

Spinocerebellar Ataxias: Therapeutic Assessment

This segment of the report provides insights about the different Spinocerebellar Ataxias drugs segregated based on following parameters that define the scope of the report, such as:

  • Major Players in Spinocerebellar Ataxias

There are approx. 3+ key companies which are developing the therapies for Spinocerebellar Ataxias. The companies which have their Spinocerebellar Ataxias drug candidates in the most advanced stage, i.e. phase III include, Kissei Pharmaceutical.

  • Phases

DelveInsight’s report covers around 3+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Spinocerebellar Ataxias pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • intravitreal
  • Subretinal
  • Topical.
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Spinocerebellar Ataxias: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Spinocerebellar Ataxias therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Spinocerebellar Ataxias drugs.

Report Highlights

  • The companies and academics are working to assess challenges and seek opportunities that could influence Spinocerebellar Ataxias R&D. The therapies under development are focused on novel approaches to treat/improve Spinocerebellar Ataxias

Spinocerebellar Ataxias Report Insights

  • Spinocerebellar Ataxias Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Spinocerebellar Ataxias Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Spinocerebellar Ataxias drugs?
  • How many Spinocerebellar Ataxias drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Spinocerebellar Ataxias?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Spinocerebellar Ataxias therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Spinocerebellar Ataxias and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Kissei Pharmaceutical

Key Products

  • KPS-0373



Executive Summary

Spinocerebellar Ataxias: Overview

• Causes

• Mechanism of Action

• Signs and Symptoms

• Diagnosis

• Disease Management

Pipeline Therapeutics

• Comparative Analysis

Therapeutic Assessment

• Assessment by Product Type

• Assessment by Stage and Product Type

• Assessment by Route of Administration

• Assessment by Stage and Route of Administration

• Assessment by Molecule Type

• Assessment by Stage and Molecule Type

Spinocerebellar Ataxias – DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

• Spinocerebellar Ataxias companies’ collaborations, Licensing, Acquisition -Deal Value Trends

Spinocerebellar Ataxias Collaboration Deals

• Company-Company Collaborations (Licensing / Partnering) Analysis

• Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

• Comparative Analysis

KPS-0373: Kissei Pharmaceutical

• Product Description

• Research and Development

• Product Development Activities

Mid Stage Products (Phase II)

• Comparative Analysis

Metopimazine: Neurogastrx

• Product Description

• Research and Development

• Product Development Activities

Drug profiles in the detailed report…..

Early Stage Products (Phase I)

• Comparative Analysis

Renzapride: Atlantic Healthcare

• Product Description

• Research and Development

• Product Development Activities

Drug profiles in the detailed report…..

Pre-clinical and Discovery Stage Products

• Comparative Analysis

RQ 00201894: RaQualia Pharma

• Product Description

• Research and Development

• Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

• Comparative Analysis

Spinocerebellar Ataxias Key Companies

Spinocerebellar Ataxias Key Products

Spinocerebellar Ataxias - Unmet Needs

Spinocerebellar Ataxias - Market Drivers and Barriers

Spinocerebellar Ataxias - Future Perspectives and Conclusion

Spinocerebellar Ataxias Analyst Views

Spinocerebellar Ataxias Key Companies


List of Table

 Table 1 Total Products for Gastroparesis

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List of Figures

 Figure 1 Total Products for Gastroparesis

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

• Kissei Pharmaceutical

  • Tags:
  • Spinocerebellar Ataxias Pipeline
  • Spinocerebellar Ataxias clinical tr...
  • Spinocerebellar Ataxias companies
  • Spinocerebellar Ataxias drugs
  • Spinocerebellar Ataxias therapies
  • Spinocerebellar Ataxias treatment a...
  • Spinocerebellar Ataxias pipeline dr...
  • Spinocerebellar Ataxias pipeline co...

Forward to Friend

Need A Quote